E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hydrocele and Spermatocele |
|
E.1.1.1 | Medical condition in easily understood language |
Fluid filled cysts in the scrotum |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Male diseases of the urinary and reproductive systems [C12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020488 |
E.1.2 | Term | Hydrocele |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041490 |
E.1.2 | Term | Spermatocele |
E.1.2 | System Organ Class | 10038604 - Reproductive system and breast disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To examine systemic ethanol absorption as measured by alcometer results and blood tests To examine pain and complication rates 1-30 days from treatment |
|
E.2.2 | Secondary objectives of the trial |
To examine cure rates with escalating doses of ethanol and exposure times |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Testicular hydrocele or spermatocele/epididymal cyst confirmed clinically or with ultrasound - Informed consent to participate - Symptomatic hydro or spermatocele corresponding to inconvenience that can not be ignored - Patients wish to undergo treatment |
|
E.4 | Principal exclusion criteria |
- Less hat 40 years - Paternity wish - Inability to comply with discontinuation of anticoagulants as described by the Swedish society of thrombosis and hemostasis - Septated hydro or spermatocele on ultrasound - Known allergy or hypersensitivity to the study drug. - Mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study - Participates in or has recently participated in a recent clinical trial (30 days). - Previous participation in this study. - Treatment with immunostimulation drugs with ATC code L01FF (pembrolizumab, ipilimumab or equivalent). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Systemic absorption of ethanol by injection into a water or sperm hernia at 2 different doses
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
5min, 30min, 1-4 days and 30 days from treatment. |
|
E.5.2 | Secondary end point(s) |
- Pain 1-4 days after treatment at 2 different doses - Complications within 30 days after treatment at 2 different doses - Symptom, 3 months after treatment at 2 different doses
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1-4 days and 30 days and after three months from treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |